Strattera Age Range in Pediatrics
Strattera (atomoxetine) is FDA-approved for pediatric patients aged 6 years and older, with no established upper age limit in the pediatric range. The FDA label explicitly states that "the safety, efficacy, and pharmacokinetics of STRATTERA in pediatric patients less than 6 years of age have not been evaluated" 1.
FDA-Approved Age Range
- Minimum age: 6 years
- Maximum pediatric age: 18 years (transition to adult dosing thereafter)
- Not approved for children under 6 years of age 1
Clinical Context from Guidelines
The 2019 AAP clinical practice guideline reinforces this age restriction, noting that nonstimulant medications, including atomoxetine, have not received sufficient rigorous study in preschool-aged children (4-5 years) to be recommended for ADHD treatment 2. For children under 6 years, methylphenidate is the recommended first-line medication when pharmacotherapy is needed, though even this remains off-label in that age group.
Important Clinical Considerations
Key safety monitoring requirements before initiating atomoxetine:
- Obtain personal and family cardiac history (sudden death, cardiovascular symptoms, Wolff-Parkinson-White syndrome, hypertrophic cardiomyopathy, long QT syndrome)
- Perform ECG if cardiac risk factors are present
- Consider pediatric cardiology referral if ECG abnormalities detected 2
FDA Black Box Warning: Atomoxetine carries a black box warning for increased suicidal ideation in children and adolescents, requiring close monitoring especially during treatment initiation 2.
Off-Label Use in Younger Children
While not FDA-approved, emerging research suggests atomoxetine may be used off-label in children aged 3-6 years with ADHD and comorbid autism spectrum disorder, though this requires careful risk-benefit assessment 3. In one retrospective study of 133 children aged 3-6 years, 37.6% experienced adverse events, with 17.3% discontinuing treatment. However, this remains investigational and should not be considered standard practice.
The established, FDA-approved age range remains 6 years and older for routine clinical use.